Atossa Therapeutics appoints Kathy Puyana Theall and Adebola Giwa as medical directors

Reuters03-19

Atossa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> appoints Kathy Puyana Theall and Adebola Giwa as medical directors

Atossa engaged Kathy Puyana Theall as Medical Director - Breast Oncology and Adebola Giwa as Medical Director - Rare Diseases.
Kathy Puyana Theall previously served as Vice President of Clinical Development - Breast Cancer at Stemline-Menarini.
She also held senior roles at Pfizer and worked in academic medicine at Tufts Medical Center.
Adebola Giwa most recently served as Senior Medical Director at Maze Therapeutics.
He previously held roles at Angitia Biopharma and Ascendis Pharma, and founded AdeBolus Medical Consulting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603190800PR_NEWS_USPR_____SF14079) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620723247?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620723247","market":"nz","top_or_hot":-1,"title":"Atossa Therapeutics appoints Kathy Puyana Theall and Adebola Giwa as medical directors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> appoints Kathy Puyana Theall and Adebola Giwa as medical directors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Atossa engaged Kathy Puyana Theall as Medical Director - Breast Oncology and Adebola Giwa as Medical Director - Rare Diseases.\n        </li>\n<li>\n          Kathy Puyana Theall previously served as Vice President of Clinical Development - Breast Cancer at Stemline-Menarini.\n        </li>\n<li>\n          She also held senior roles at Pfizer and worked in academic medicine at Tufts Medical Center.\n        </li>\n<li>\n          Adebola Giwa most recently served as Senior Medical Director at <a href=\"https://laohu8.com/S/MAZE\">Maze Therapeutics</a>.\n        </li>\n<li>\n          He previously held roles at Angitia Biopharma and Ascendis Pharma, and founded AdeBolus Medical Consulting.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603190800PR_NEWS_USPR_____SF14079) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atossa Therapeutics appoints Kathy Puyana Theall and Adebola Giwa as medical directors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtossa Therapeutics appoints Kathy Puyana Theall and Adebola Giwa as medical directors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> appoints Kathy Puyana Theall and Adebola Giwa as medical directors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Atossa engaged Kathy Puyana Theall as Medical Director - Breast Oncology and Adebola Giwa as Medical Director - Rare Diseases.\n        </li>\n<li>\n          Kathy Puyana Theall previously served as Vice President of Clinical Development - Breast Cancer at Stemline-Menarini.\n        </li>\n<li>\n          She also held senior roles at Pfizer and worked in academic medicine at Tufts Medical Center.\n        </li>\n<li>\n          Adebola Giwa most recently served as Senior Medical Director at <a href=\"https://laohu8.com/S/MAZE\">Maze Therapeutics</a>.\n        </li>\n<li>\n          He previously held roles at Angitia Biopharma and Ascendis Pharma, and founded AdeBolus Medical Consulting.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603190800PR_NEWS_USPR_____SF14079) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4534","symbol_name":"瑞士信贷持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL5c6j94:1","article_id":"2620723247","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620723247","pubTimestamp":1773921851,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Atossa engaged Kathy Puyana Theall as Medical Director - Breast Oncology and Adebola Giwa as Medical Director - Rare Diseases.Kathy Puyana Theall previously served as Vice President of Clinical Development - Breast Cancer at Stemline-Menarini.She also held senior roles at Pfizer and worked in academic medicine at Tufts Medical Center.Adebola Giwa most recently served as Senior Medical Director at Maze Therapeutics.He previously held roles at Angitia Biopharma and Ascendis Pharma, and founded AdeBolus Medical Consulting.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4534":"瑞士信贷持仓","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999002232.USD":"Allianz Global High Payout USD","ATOS":"Atossa Genetics Inc","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4592":"伊斯兰概念","BK4559":"巴菲特持仓","BK4135":"资产管理与托管银行","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4588":"碎股","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4007":"制药","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4599":"减肥药","BK4581":"高盛持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4585":"ETF&股票定投概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4139":"生物科技"},"translate_title":"Atossa Therapeutics任命Kathy Puyana Theall和Adebola Giwa为医疗总监","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATOS":1.86},"content_text":"Atossa Therapeutics appoints Kathy Puyana Theall and Adebola Giwa as medical directors\n    \n\n\n          Atossa engaged Kathy Puyana Theall as Medical Director - Breast Oncology and Adebola Giwa as Medical Director - Rare Diseases.\n        \n\n          Kathy Puyana Theall previously served as Vice President of Clinical Development - Breast Cancer at Stemline-Menarini.\n        \n\n          She also held senior roles at Pfizer and worked in academic medicine at Tufts Medical Center.\n        \n\n          Adebola Giwa most recently served as Senior Medical Director at Maze Therapeutics.\n        \n\n          He previously held roles at Angitia Biopharma and Ascendis Pharma, and founded AdeBolus Medical Consulting.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603190800PR_NEWS_USPR_____SF14079) on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620723247","isCrawlerRequest":true}